中文摘要：

目的：观察急性白血病（AL）血清中可溶性细胞间黏附分子-1（sICAM-1）和可溶性血管细胞间黏附分子-1（sVCAM-1）的表达水平及其临床意义。方法：在60例初诊AL，以及治疗后达到完全缓解（CR）的16例患者中采集外周血分离出血清。采用酶联免疫吸附试验（ELISA）方法检测sICAM-1和sVCAM-1的水平，并探讨其与临床特征之间的关系。结果：在初诊AL患者中sICAM—1和sVCAM-1的水平明显高于CR组和正常对照组．CR组sICAM-1与sVCAM-1水平和正常对照组无显著差异（P〈0．01，P〈0.01）。在初诊AL中，能够达到CR的患者其sICAM-1与sVCAM-1水平要低于未达到CR患者（P〈0．05．P〈0．05）。在高自细胞白血病（WBC〉100×10^9／L）中，sICAM-1和sVCAM-1的水平和其他非高白细胞白血病无差异（P=0．059．P=0．146）。具有良好核型组和其对应组之间sICAM-1和sVCAM-1无统计学差异（P=0．262．P=0．558）。sICAM-1和sVCAM-1不同水平的患者生存期无差异。结论：AL血清sICAM-1和sVCAM-1表达水平异常且影响疗效．但无预后意义。

英文摘要：

Objective：To investigate the levels of soluble intercellular adhesion molecule-1 （sICAM-1） and soluble vascular cell adhesion molecule-1 （sVCAM-1） in serum of patients with acute leukemia（AL） and evaluate their clinical significance. Methods： Sixty untreated patients with AL （39 with acute non-lymphoid leukemia, 21 with acute lymphoid leukemia） were included in this study. Serum levels of sICAM-1 and sVCAM-1 were determined using commercially available immunoassays （ELISA）. In addition, twelve healthy volunteers were studied as control. Results：Serum sICAM-1 and sVCAM-1 levels were significantly higher in untreated patients than those in control and the complete remission group （P 〈 0.001, P 〈 0.001 ）. In initial diagnosed patients with AL, the patient who achieved CR showed lower levels of sICAM-1 和 sVCAM-1 than those without CR （P 〈 0.05, P 〈 0.05）. While the difference of the serum levels of sICAM-1 and sVCAM-1 between CR group with control group was not significant, The patients with different levels of sICAM-1 or sVCAM-1 showed no statistical difference in overall survival. Conclusion：Serum levels of sICAM-1 and sVCAM-1 in patients with AL are abnormal which influence the therapeutic efficiency but bad no prognostic significance.